TP53 and cancer: Despite their reduced sensitivity, the IC50 for ONC‐212 against TP53ko CLL cells was still in the nanomolar range, which is consistent with previous studies demonstrating the efficacy of the imipridones against cancers harbouring mutations of TP53 [38].